ProPhase Labs Inc - Asset Resilience Ratio
ProPhase Labs Inc (PRPH) has an Asset Resilience Ratio of 0.00% as of June 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Check PRPH capital-intensive asset ratio to assess the company's strategic physical and investment asset allocation.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2011–2024)
This chart shows how ProPhase Labs Inc's Asset Resilience Ratio has changed over time. See ProPhase Labs Inc (PRPH) balance sheet quality index to measure how much of total assets are equity-financed.
Liquid Assets Composition Over Time
This chart breaks down ProPhase Labs Inc's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see PRPH market cap.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0% |
| Short-term Investments | $2.00K | 0.0% |
| Total Liquid Assets | $2.00K | 0.00% |
Asset Resilience Insights
- Limited Liquidity: ProPhase Labs Inc maintains only 0.00% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company has significant short-term investments, indicating active treasury management.
ProPhase Labs Inc Industry Peers by Asset Resilience Ratio
Compare ProPhase Labs Inc's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Fleury S.A.
SA:FLRY3 |
Diagnostics & Research | 16.06% |
|
Wuhan Thalys Med Tech Co Ltd
SHG:603716 |
Diagnostics & Research | 0.12% |
|
Spectral Med Inc
TO:EDT |
Diagnostics & Research | 11.67% |
|
Bcal Diagnostics Ltd
AU:BDX |
Diagnostics & Research | 0.00% |
|
Genetic Signatures Ltd
AU:GSS |
Diagnostics & Research | 60.91% |
|
Sonic Healthcare Ltd
AU:SHL |
Diagnostics & Research | 0.13% |
|
Australian Clinical Labs Ltd
AU:ACL |
Diagnostics & Research | 4.11% |
|
Monash Ivf Group Ltd
AU:MVF |
Diagnostics & Research | 1.60% |
Annual Asset Resilience Ratio for ProPhase Labs Inc (2011–2024)
The table below shows the annual Asset Resilience Ratio data for ProPhase Labs Inc.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2024-12-31 | 0.00% | $0.00 | $63.20 Million | -- |
| 2023-12-31 | 3.40% | $3.13 Million | $91.93 Million | -6.10pp |
| 2022-12-31 | 9.50% | $8.33 Million | $87.65 Million | -0.41pp |
| 2021-12-31 | 9.92% | $8.86 Million | $89.30 Million | +4.70pp |
| 2020-12-31 | 5.22% | $1.64 Million | $31.41 Million | -2.33pp |
| 2019-12-31 | 7.54% | $926.00K | $12.27 Million | -24.70pp |
| 2018-12-31 | 32.25% | $6.69 Million | $20.74 Million | -22.68pp |
| 2017-12-31 | 54.93% | $18.77 Million | $34.16 Million | -- |
| 2016-12-31 | 0.00% | $0.00 | $12.80 Million | -- |
| 2015-12-31 | 0.00% | $0.00 | $14.83 Million | -- |
| 2014-12-31 | 0.00% | $0.00 | $16.06 Million | -- |
| 2013-12-31 | 0.00% | $0.00 | $17.42 Million | -- |
| 2012-12-31 | 0.00% | $0.00 | $16.66 Million | -- |
| 2011-12-31 | 0.00% | $0.00 | $19.08 Million | -- |
About ProPhase Labs Inc
ProPhase Labs, Inc. develops and commercializes novel drugs, dietary supplements, and compounds in the United States. It operates through two segments: Diagnostic Services and Consumer Products. The company provides a range of dietary supplements under the TK supplements, including Legendz XL, a male sexual enhancement; and Triple Edge XL, an energy and stamina booster. It also develops BE-Smart … Read more